Lilly Forteo Labeling Talks Last Step Before Approval; GMP Issues Resolved
Executive Summary
Lilly completion of Forteo labeling negotiations with FDA is the only remaining hurdle before final approval, following the resolution of manufacturing issues for the osteoporosis agent
You may also be interested in...
Lilly GMPs Will Not Deter Product Rollout, Firm Says
The remaining Lilly products delayed by good manufacturing practices compliance problems could be approved by FDA before the company has fully implemented its GMP improvement program
Lilly GMPs Will Not Deter Product Rollout, Firm Says
The remaining Lilly products delayed by good manufacturing practices compliance problems could be approved by FDA before the company has fully implemented its GMP improvement program
Lilly Vancocin Discontinued: Inventory Distributed To CAPD Patients
Lilly is working with FDA to set up a distribution program to provide the remaining inventory of Vancocin to CAPD patients following the company's decision to discontinue its injectable and oral solution vancomycin